In a recent interview with ILCN, the US FDA’s Dr. Harpreet Singh discusses the confirmatory Pragmatica-Lung trial and how the agency’s new pragmatic approach to trial design can streamline research and ultimately benefit patients. Read more
Stephen Liu, MD, and Tina Cascone, MD, PhD, share what attendees can expect at the first ever Texas Lung Cancer Conference, an upcoming two-day CME meeting endorsed by the IASLC. Read more
In addressing fellow TTLC 23 faculty, Dr. Langer recounted the perils and pitfalls, promises and poetry he has experienced in his 35 years in the field. Read more
Dr. Lyudmila Bazhenova argues the drug’s superior PFS makes it the best first choice; however Dr. Justin Gainor says toxicity data show it may not be right for all patients. Read more
During TTLC 23, Johns Hopkins’ Tia Cheunkarndee presented data that highlight the vast heterogeneity of mutations—and their variable response to treatment. Read more
In a recent interview with ILCN, Dr. Karen Reckamp discussed the overall survival implications from the phase II Lung-MAP study and how the phase III follow-up Pragmatica-Lung trial aims to confirm that specific endpoint. Read more
In a Q&A with ILCN, new JTO Clinical and Research Reports Editor-in-Chief Dr. Emily Stone discusses her passion for tobacco control and the importance of open-access journals in elevating research globally. Read more
Patient advocate Dusty Donaldson says for most patients regular surveillance is not the problem and points out limitations of data that fail to show better outcomes with frequent scanning. Read more
During the Targeted Therapies of Lung Cancer meeting, MD Anderson’s Dr. Lauren Byers celebrated recent advances and highlighted areas in need of further research. Read more
During TTLC 23, Drs. Balazs Halmos and Mark Socinski presented the evidence for and against continued tyrosine kinase inhibitors use with chemotherapy for EGFR-positive patients with disease progression. Read more